Shattuck Labs (STTK) Non-Current Deffered Revenue (2019 - 2021)
Shattuck Labs (STTK) posted quarterly Non-Current Deffered Revenue of $2.2 million for Q4 2021, down 89.61% year-over-year from $21.3 million in Q4 2020, and down 91.89% quarter-over-quarter from $27.3 million in Q3 2021.
Shattuck Labs (STTK) Non-Current Deffered Revenue (2019 - 2021) Analysis & Trends
Shattuck Labs (STTK) has reported Non-Current Deffered Revenue for 3 consecutive years, with $2.2 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Non-Current Deffered Revenue fell 89.61% year-over-year to $2.2 million; the TTM figure through Dec 2021 stood at $2.2 million (down 89.61% YoY), while the FY2021 annual figure was $2.2 million, down 89.61% from the prior year.
- Non-Current Deffered Revenue fell to $2.2 million in Q4 2021 per STTK's latest filing, from $27.3 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $29.2 million in Q2 2021 and bottomed at $898000.0 in Q4 2019.
- Historically, Non-Current Deffered Revenue has averaged $12.0 million across 3 years, with a median of $2.2 million in 2021.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 2894.18% in 2021 and fell as far as 89.61% in 2021.
- Shattuck Labs' Non-Current Deffered Revenue stood at $898000.0 in 2019, then soared by 2272.61% to $21.3 million in 2020, then tumbled by 89.61% to $2.2 million in 2021.
- Business Quant data shows STTK's Non-Current Deffered Revenue at $2.2 million in Q4 2021, $27.3 million in Q3 2021, and $29.2 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 2.21 Mn |
| Sep 30, 2021 | 27.28 Mn |
| Jun 30, 2021 | 29.22 Mn |
| Mar 31, 2021 | 2.20 Mn |
| Dec 31, 2020 | 21.31 Mn |
| Sep 30, 2020 | 911,000.00 |
| Dec 31, 2019 | 898,000.00 |